The EVH system used in the PREVENT IV trial was a closed gas (CO2) system. EVH systems dependent on gas insufflation to maintain tissue separation and/or the tunnel carry an increased risk of CO2 embolism. Sorin Group’s ClearGlide system is an Open CO2 system, which carries little or no risk of CO2 embolism.
In addition, there are several additional factors that make ClearGlide a safe EVH option for your patients, as illustrated in the comparison chart below:
EVH System A
EVH System B
Sorin ClearGlide
Open CO2 System
No
No
Yes
Lockable Jaw
No
No
Yes
Low Operating Temperature
No
No
Yes (28°)
Reduced Risk of Clot Formation
No
No
Yes
Reduced Risk of CO2 Embolism
No
No
Yes
Reduced Risk of Wound Complications
Yes
Yes
Yes
Required Degree of Vein Manipulation
Moderate
Moderate
Low
Reduced Risk of Intimal Hyperplasia
No
No
Yes
Caution: Federal law (USA) restricts this device to sale by or on the order of a physician.
For indications, contraindications, precautions and warnings for each device, please refer to the Instructions For Use.